Live Breaking News & Updates on Acrivon therapeutics inc

Stay updated with breaking news from Acrivon therapeutics inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Acrivon Therapeutics (NASDAQ:ACRV) & ADC Therapeutics (NYSE:ADCT) Critical Analysis

Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) and ADC Therapeutics (NYSE:ADCT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends. Profitability This table compares Acrivon Therapeutics and […]

Watertown , Massachusetts , United-states , Switzerland , Epalinges , Switzerland-general- , Mitsubishi-tanabe-pharma-corporation , Acrivon-therapeutics-inc , Overland-pharmaceuticals , Acrivon-therapeutics , Get-free-report

Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $24.00

Acrivon Therapeutics (NASDAQ:ACRV) Price Target Cut to $24.00
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , California , Wells-fargo-company , Barclays-plc , York-state-common-retirement-fund , Acrivon-therapeutics-company-profile , Acrivon-therapeutics-inc , Citigroup-inc , Maxim-group , Acrivon-therapeutics

BMO Capital Markets Trims Acrivon Therapeutics (NASDAQ:ACRV) Target Price to $24.00

BMO Capital Markets Trims Acrivon Therapeutics (NASDAQ:ACRV) Target Price to $24.00
modernreaders.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernreaders.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , California , Wells-fargo-company , Acrivon-therapeutics-inc , Barclays-plc , York-state-common-retirement-fund , Citigroup-inc , Maxim-group , Acrivon-therapeutics-company-profile , Acrivon-therapeutics

Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $23.00

Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are currently covering the company, Marketbeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokerages that have updated their coverage on […]

Barclays-plc , Maxim-group , Marshall-wace , Nasdaq , Millennium-management , Acrivon-therapeutics-inc , Acrivon-therapeutics , Get-free-report , Marketbeat-ratings , Sigma-investments , Therapeutics-trading-down

Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 ...

Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as

Boston , Massachusetts , United-states , Watertown , Peter-blume-jensen , Alexandra-santos , Drug-administration , Acrivon-therapeutics-inc , Exchange-commission , International-conference-on-molecular , Acrivon-predictive-precision-proteomics , Acrivon-therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) Now Covered by Maxim Group

Analysts at Maxim Group assumed coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) in a research report issued to clients and investors on Thursday, FlyOnTheWall reports. The brokerage set a “buy” rating on the stock. A number of other research analysts have also weighed in on ACRV. HC Wainwright reaffirmed a “buy” […]

California , United-states , New-york , York-state-common-retirement-fund , Wells-fargo-company , Citigroup-inc , Barclays-plc , Acrivon-therapeutics-inc , Acrivon-therapeutics-company-profile , Analysts-at-maxim-group , Maxim-group

Analysts' New Coverage for October 5th (AAU, ACRV, AEZS, AME, APH, AWX, BGI, BLPH, BNCZF, CAKE)

Analysts’ new coverage for Thursday, October 5th: StockNews.com assumed coverage on shares of Almaden Minerals (NYSE:AAU). They issued a sell rating on the stock. Maxim Group initiated coverage on shares of Acrivon Therapeutics (NASDAQ:ACRV). They issued a buy rating and a $24.00 target price on the stock. StockNews.com assumed coverage on shares of Aeterna Zentaris […]

United-states , Argentina , America , Janney-montgomery-scott , Societe-generale , Redburn-atlantic , Sanfordc-bernstein , Stifel-nicolaus , Innsuites-hospitality-trust , Citigroup-inc , Almaden-minerals , Barclays-plc

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Sept. 28, 2023 -- Acrivon Therapeutics, Inc. , a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are...

Adam-levy , Alexandra-santos , Exchange-commission , Drug-administration , Acrivon-therapeutics-inc , Nasdaq-rule , Acrivon-predictive-precision-proteomics , Private-securities-litigation-reform-act , Media-contacts , Markets ,

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
wallstreet-online.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wallstreet-online.de Daily Mail and Mail on Sunday newspapers.

Acrivon-therapeutics-inc ,